-
Evolutionary classification of protein domains: Unveiling protein functions and advancing drug discovery蛋白质域的进化分类：揭示蛋白质功能并推动药物发现
-
Advances in Protein and Polypeptide Drug Analytics蛋白质和多肽药物分析进展
-
Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems基于蛋白质的纳米颗粒药物递送系统在炎症性肠病口服治疗中的进展
-
The Research Progress on Dynamic Covalent Bonding-based Nanocarriers for Protein Drug Delivery基于动态共价键合的纳米载体用于蛋白质药物递送的研究进展
-
Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems.利用基于蛋白质的纳米颗粒药物递送系统治疗炎症性肠病的口服治疗进展
-
Recent Advances in Targeted Protein Degradation Molecular Glues as Anticancer Drugs靶向蛋白降解分子胶作为抗癌药物的最新进展
-
Constructing a High-Affinity Nanobody Targeting the RSV pre-F Protein Based on AIDD and Site-Directed Mutagenesis: An Advanced In-Silico Drug Discovery Method基于AIDD和定点诱变构建靶向RSV pre-F蛋白的高亲和力纳米抗体：一种先进的计算机辅助药物发现方法
-
Recent Advances in Targeted Protein Degradation Molecular Glues as Anticancer Drugs.靶向蛋白降解分子胶作为抗癌药物的最新进展
-
Advances in protein-protein interaction inhibitors (PPIs): drug discovery strategies.蛋白质-蛋白质相互作用抑制剂（PPIs）进展：药物发现策略
-
Advances in Protein and Polypeptide Drug Analytics.蛋白质和多肽药物分析进展
-
Protein based nanoparticles for pulmonary drug delivery: advances, challenges, and future perspectives用于肺部药物递送的蛋白质基纳米颗粒：进展、挑战和未来展望
-
Composition useful for treating advanced or metastatic solid malignant tumors e.g. gastrointestinal tumor or non-small cell lung cancer comprises programmed death ligand 1 (PD-L1) binding molecule and protein-drug conjugate用于治疗晚期或转移性实体恶性肿瘤（如胃肠道肿瘤或非小细胞肺癌）的组合物，包括程序性死亡配体1（PD-L1）结合分子和蛋白-药物偶联物
-
Use of programmed death ligand 1 binding molecule in drug combination for improving stability of protein-drug conjugate preparations, and treating advanced or metastatic solid malignant tumor程序性死亡配体1结合分子在药物组合中用于提高蛋白-药物偶联物制剂的稳定性，并治疗晚期或转移性实体恶性肿瘤
-
A phase 1 dose escalation/expansion study of GSK5764227, a B7homolog 3 protein targeted antibody-drug conjugate, in combination with standard of care in patients with advanced solid tumors FreeGSK5764227（一种靶向B7同源物3蛋白的抗体-药物偶联物）在晚期实体瘤患者中联合标准治疗的1期剂量递增/扩展研究
-
Research Advances for Protein-Based Pickering Emulsions as Drug Delivery Systems基于蛋白质的Pickering乳液作为药物递送系统的研究进展
-
Research progress on antiviral drugs targeting SARS-CoV-2 nucleocapsid protein.靶向SARS-CoV-2核衣壳蛋白的抗病毒药物研究进展
-
Advances in the Oral Delivery of Protein and Peptide Drugs蛋白质和多肽类药物口服递送的进展
-
Research Progress on Biogenic Protein Nano-drug Delivery Systems: Taking Albumin, Silk Fibroin and Zein as Examples生物源蛋白纳米药物递送系统的研究进展：以白蛋白、丝素蛋白和玉米醇溶蛋白为例
-
Treating and preventing progression of cancer e.g. gastric cancer includes administering anti-programmed cell death protein 1 antibody and anti-human epidermal growth factor receptor 2 antibody-drug conjugate and cytotoxic molecule治疗和预防癌症（如胃癌）的进展包括施用抗程序性细胞死亡蛋白1抗体和抗人表皮生长因子受体2抗体-药物偶联物以及细胞毒性分子
-
A phase I dose escalation/expansion study of GSK5764227 (GSK'227), a B7-homologue 3 (B7-H3) protein-targeted antibody-drug conjugate (ADC), in combination with standard of care (SoC), in patients with advanced solid tumours, including lung cancersGSK5764227（GSK'227）的I期剂量递增/扩展研究，GSK5764227是一种靶向B7同源物3（B7-H3）蛋白的抗体-药物偶联物（ADC），联合标准治疗（SoC），用于治疗包括肺癌在内的晚期实体瘤患者